Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?

Area of Science:

• Oncology
• Pharmacology
• Drug Delivery

Background:

• Tyrosine kinase inhibitors (TKIs) are crucial targeted cancer therapies, with over 100 approved in 22 years.
• Despite efficacy, TKIs present administration challenges including food-drug interactions, acid-reducing agent (ARA) interference, high pill burden, and frequent dosing.

Purpose of the Study:

• To review TKI administration challenges and identify innovative solutions.
• To analyze trends in TKI labeling regarding food effects and ARA interactions.
• To suggest formulation strategies for improved patient compliance and efficacy.

Main Methods:

• Data compilation of 94 TKIs approved between 2000-2022.
• Analysis of food effect, ARA impact, administration schemes, pill burden, and dosing frequency.
• Trend analysis to identify labeling inconsistencies and explore novel formulation approaches.
• Discussion of physiologically based pharmacokinetic (PBPK) modeling for formulation development.

Main Results:

• Identified inconsistencies between observed food effects and TKI labeling.
• Highlighted TKIs affected by ARA co-administration.
• Revealed opportunities for reducing pill burden and dosing frequency through innovative formulations.
• Demonstrated the utility of PBPK modeling in rational TKI formulation.

Conclusions:

• Addressing TKI administration challenges is critical for optimizing cancer treatment.
• Novel formulation approaches and PBPK modeling can overcome TKI restrictions.
• This review serves as a guide for developing improved TKI therapies and enhancing patient compliance.